Pharmaceutical

Janssen seeks EMA approval of RYBREVANT for NSCLC

Janssen has filed a Type II extension of indication application with the EMA seeking approval for Rybrevant for NSCLC.

Feb 10, 2024 - 18:00
Janssen seeks EMA approval of RYBREVANT for NSCLC
Janssen has filed a Type II extension of indication application with the EMA seeking approval for Rybrevant for NSCLC.
Read the original article

Tags:

Previous Article

Pharma and biotech concerned about the stability of large CROs, survey finds

Next Article

Boehringer and CBmed partner to develop cancer therapies

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

NA-921 by Biomed Industries for Rett Syndrome: Likeliho...

Feb 20, 2024

Biden officials propose slate of Medicaid transparency changes

Biden officials propose slate of Medicaid transparency ...

Apr 27, 2023

DBV sets course on regulatory journey for peanut allergy patch

DBV sets course on regulatory journey for peanut allerg...

Apr 20, 2023